Teva to present CNS drug data at AAN annual meeting

Teva will be showcasing clinical trial data on a number of new central nervous system (CNS) disease treatments at this month's American Academy of Neurology (AAN) annual meeting.

During the New Orleans conference, the organisation will present 30 abstracts detailing information on multiple therapies, including established products and investigational therapies.

The market-leading relapsing-remitting multiple sclerosis treatment Copaxone will be the focus of several featured presentations, including trials that show its benefits in reducing spasticity rates among patients.

Meanwhile, the developmental oral therapy laquinomod will be showcased in pooled analyses of the phase III Allegro and Bravo trials, showing how it can help to minimise annualised relapse rates.

Further abstracts will also offer insight into therapies such as armodafinil and Azilect.

Last month, the company reported positive data from Allegro highlighting the benefits of laquinomod, results which will be used to support the drug's application for European approval.